Morepen Laboratories Limited — Investor Meet, 17-05-2025: Analysts/Institutional Investor Meet/Con. Call Updates

Morepen Laboratories has announced a board meeting to consider the financial results for the quarter and half-year. FY25 revenue rose 7.4% YoY to INR1,830 Cr, with EBITDA margin improving to 10.5% and PAT growing 22%, despite some export delays. API contributes 53% of revenue, exports 72%, with volumes up 57% despite a 24% drop in prices over two years. API capacity is set to double by FY26. Formulations grew 29% QoQ, driven by an expanding sales force and new diabetic/cardiac products. Medical devices (27% of business) grew 12% annually, with strong meter and test strip sales and ongoing capacity expansion. Management is confident about margin gains from product mix, exports, and capacity ramp-up, targeting 10-15% revenue growth over FY26-27.